Get the Stockscreener App
17.07
1.16%
0.195
Beta Bionics Inc stock is traded at $17.07, with a volume of 296.66K.
It is up +1.16% in the last 24 hours and down -11.26% over the past month.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
See More
Previous Close:
$16.87
Open:
$16.98
24h Volume:
296.66K
Relative Volume:
0.30
Market Cap:
$920.59M
Revenue:
$110.24M
Net Income/Loss:
$-66.44M
P/E Ratio:
-11.29
EPS:
-1.5111
Net Cash Flow:
$-61.12M
1W Performance:
-2.09%
1M Performance:
-11.26%
6M Performance:
+31.07%
1Y Performance:
-19.24%
1-Day Range:
$16.60
$17.60
1-Week Range:
$16.72
$18.56
52-Week Range:
$8.80
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
Name
Beta Bionics Inc
Sector
Industry
Phone
949-427-7785
Address
11 HUGHES, IRVINE
Compare BBNX vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
17.07 | 920.59M | 110.24M | -66.44M | -61.12M | -1.5111 |
ABT
Abbott Laboratories
|
104.47 | 180.77B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.28 | 121.88B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
291.70 | 111.89B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.77 | 63.43B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.59 | 49.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Initiated | Jefferies | Buy |
| Oct-07-26 | Initiated | Barclays | Overweight |
| Sep-23-26 | Initiated | Wells Fargo | Overweight |
| Aug-21-26 | Initiated | William Blair | Mkt Perform |
| Jul-28-26 | Resumed | UBS | Buy |
| Feb-09-26 | Initiated | UBS | Buy |
| Jan-27-26 | Initiated | TD Cowen | Hold |
| Jan-09-26 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-21-25 | Resumed | Stifel | Buy |
| Oct-01-25 | Upgrade | Goldman | Neutral → Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| Jun-12-25 | Initiated | Lake Street | Buy |
| May-30-25 | Initiated | Goldman | Neutral |
| May-30-25 | Initiated | Wolfe Research | Outperform |
| Feb-24-25 | Initiated | BofA Securities | Buy |
| Feb-24-25 | Initiated | Lake Street | Buy |
| Feb-24-25 | Initiated | Leerink Partners | Outperform |
| Feb-24-25 | Initiated | Piper Sandler | Overweight |
| Feb-24-25 | Initiated | Stifel | Buy |
| Feb-20-25 | Initiated | Ladenburg Thalmann | Neutral |
| Feb-20-25 | Initiated | Robert W. Baird | Neutral |
View All
Beta Bionics Inc Stock (BBNX) Latest News
Beta Bionics, Inc. Class Action ReminderRobbins LLP Encourages BBNX Investors to Contact the Firm for Information About Their Rights - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Beta Bionics, Inc. Notice of November 3, 2026 Application - GlobeNewswire
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - GlobeNewswire Inc.
AEVEX Corp. Notice of October 20, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX - GlobeNewswire Inc.
Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm Before the Securities Class Action Deadline on November 3, 2026 - The Globe and Mail
BETA BIONICS, INC. (BBNX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBBNX - GlobeNewswire Inc.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Beta Bionics, - GlobeNewswire
Markets & Stocks - FinancialContent
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Chief commercial officer Hopman sells $7,015 of Beta Bionics stock By Investing.com - Investing.com Canada
ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBBNX - GlobeNewswire Inc.
ROSEN, A LEADING LAW FIRM, Encourages Beta Bionics, Inc. - GlobeNewswire
Kaplan Fox Notifies Investors of Beta Bionics, Inc. (NASDAQ: BBNX) of the Lead Plaintiff Deadline on November 3, 2026 - The Globe and Mail
BBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitHBSS - GlobeNewswire Inc.
BBNX ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
FinancialContentKaplan Fox Reminds Investors of a Securities Class Action Against Beta Bionics, Inc. (NASDAQ: BBNX)Deadline is November 3, 2026 - FinancialContent
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - GlobeNewswire Inc.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Beta Bionics, - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC - GlobeNewswire Inc.
BBNX Stock Notice: Beta Bionics Stock Plummeted 37% after Medical Device Safety Issues DisclosedSecurities Fraud Class Action Filed - Lelezard
Deadline Alert: Beta Bionics, Inc. (BBNX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit - Carroll County Mirror-Democrat
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit - mykxlg.com
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit - True North Radio Network
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files - GlobeNewswire
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit - Cortland Standard
BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit - YourGV.com
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBBNX - GlobeNewswire Inc.
Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc.BBNX - Morningstar
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit - Carroll County Mirror-Democrat
BBNX Investor Alert: Schall, Brown & Schwartz LLP Files - GlobeNewswire
Kaplan Fox Alerts GoDaddy Inc. (NYSE: GDDY) Investors to an Approaching Lead Plaintiff Deadline on October 20, 2026 - GlobeNewswire Inc.
Kaplan Fox Notifies Beta Bionics, Inc. (NASDAQ: BBNX) Investors of an Upcoming Lead Plaintiff Deadline on November 3, 2026 - GlobeNewswire Inc.
Kaplan Fox Reminds Beta Bionics, Inc. (NASDAQ: BBNX) Investors With Significant Losses to Seek a Leadership Role Before Deadline on November 3, 2026 - The Globe and Mail
Beta Bionics, Inc. (BBNX) stock price, news, quote and history - Yahoo Finance UK
רוזן, משרד מוביל בפריסה ארצית המייצג משקיעים, מעודד את משקיעי חברת Beta Bionics, Inc לשכור ייעוץ משפטי לקראת מועד אחרון חשוב במסגרת תביעה ייצוגית בניירות ערך – BBNX - GlobeNewswire Inc.
Beta Bionics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Beta Bionics, Inc.BBNX - GlobeNewswire Inc.
ROSEN, TOP-RANKED TRIAL ATTORNEYS, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCS - GlobeNewswire Inc.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionQFIN - GlobeNewswire Inc.
ROSEN, A NATIONAL AND LEADING INVESTOR RIGHTS FIRM, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBBNX - GlobeNewswire Inc.
ROSEN, A NATIONAL AND LEADING INVESTOR RIGHTS FIRM, - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
BETA BIONICS, INC. (BBNX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Beta Bionics, Inc. Notice of November 3, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - GlobeNewswire Inc.
Robbins LLP Urges BBNX Stockholders to Contact the Firm for Information About the Class Action Against Beta Bionics, Inc. - PR Newswire
Beta Bionics Inc Stock (BBNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beta Bionics Inc Stock (BBNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MARK HOPMAN | Officer |
Oct 01 '26 |
Proposed Sale |
18.98 |
2,660 |
50,487 |
0 |
| Jones Christy | Director |
Sep 22 '26 |
Sale |
23.00 |
6,430 |
147,890 |
19,564 |
| CHRISTINA JONES | Director |
Sep 22 '26 |
Proposed Sale |
22.04 |
8,942 |
197,082 |
0 |
| MICHAEL MENSINGER | Officer |
Sep 16 '26 |
Proposed Sale |
19.23 |
5,300 |
101,919 |
0 |
| Mensinger Mike | Chief Product Officer |
Sep 16 '26 |
Sale |
22.00 |
2,650 |
58,300 |
177,390 |
| Hopman Mark | Chief Commercial Officer |
Sep 16 '26 |
Sale |
20.13 |
30,779 |
619,640 |
56,479 |
| MARK HOPMAN | Officer |
Sep 16 '26 |
Proposed Sale |
19.23 |
28,119 |
540,728 |
0 |
| Hopman Mark | Chief Commercial Officer |
Sep 14 '26 |
Sale |
15.52 |
775 |
12,028 |
86,382 |
| MARK HOPMAN | Officer |
Sep 09 '26 |
Proposed Sale |
19.33 |
40,305 |
779,096 |
0 |
| Hopman Mark | Chief Commercial Officer |
Sep 09 '26 |
Sale |
18.46 |
36,870 |
680,723 |
87,157 |
1.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):